Good hair-loss advice around finasteride minoxidil prp has to separate visible change from camera noise, panic, and marketing. The practical value is in staging the pattern, understanding options, and avoiding promises no one can honestly make from a single image.
A friend of mine, Kevin, is a 31-year-old systems engineer in Denver who spent about four months last year toggling between open browser tabs for Hims and Keeps, comparing subscription tiers, squinting at before-and-after photos, and reading Reddit threads at 1 a.m. When he finally texted me about it, his question was almost comically simple: “They sell the same drugs, right? So what am I even choosing between?” The answer is yes, mostly, and also that the choice is less consequential than people think. But getting there requires understanding what pattern hair loss actually is, how the treatments work, and where the real cost differences live.
The Biology Nobody Reads (But Should)
The story of androgenetic alopecia starts with James Hamilton’s 1951 paper in the Annals of the New York Academy of Sciences, where he noticed something striking: men castrated before puberty never developed the classic receding hairline or crown thinning. No androgens, no pattern baldness. That observation set up everything that followed.
O’Tar Norwood formalized the staging system in 1975 in the Southern Medical Journal, expanding Hamilton’s original three stages into seven, plus several subtypes (including the Type A variant, where the front retreats like a slow tide rather than opening up at the vertex). That combined Hamilton-Norwood scale has been the clinical standard for over 70 years. Newer alternatives like the BASP classification (proposed in 2007) exist. Nobody really uses them.
Here’s what matters at the follicle level. Testosterone gets converted into dihydrotestosterone (DHT) by the enzyme 5-alpha reductase. In people with the right (or wrong) genetic lottery ticket, DHT latches onto androgen receptors in the dermal papilla and slowly strangles each hair cycle. The growth phase gets shorter. The resting phase gets longer. The follicle itself physically shrinks. Thick terminal hairs become wispy vellus hairs, and eventually you’re looking at scalp where coverage used to be.
The genetics are polygenic. Yes, the androgen receptor gene on the X chromosome matters, which is why people point to your mother’s father. But autosomal loci from the paternal side contribute too, so that old “look at your mom’s dad” rule is roughly as reliable as checking the weather forecast five days out.
What Hims and Keeps Actually Sell You
Both platforms prescribe finasteride (1 mg oral, daily) and minoxidil (5% topical, twice daily). These are the same FDA-approved molecules at the same FDA-approved doses. Hims and Keeps are not pharmaceutical companies; they’re telehealth front ends that connect you to a licensed prescriber, then ship you generics or their own branded formulations.
Oral finasteride blocks the type II isoform of 5-alpha reductase, lowering scalp DHT. The landmark five-year randomized trial published in the Journal of the American Academy of Dermatology (JAAD) in 2002 showed sustained improvements in hair count versus placebo. Sexual side effects affect a small percentage of users in clinical trials and are generally reversible on discontinuation.
Topical minoxidil 5% works through mechanisms that aren’t fully pinned down (potassium channel opening, vasodilation, direct follicular effects). Multiple randomized trials show visible results at three to six months. Foam and solution are clinically equivalent, though foam causes less scalp irritation for some people.
The operational differences between the two services come down to pricing tiers, bundled add-ons (shampoos, supplements, combination topicals), subscription flexibility, and how the telehealth consultation feels. Hims has expanded into a broader men’s wellness brand; Keeps has stayed more narrowly focused on hair. Neither difference changes what finasteride does to your DHT levels.
The boring truth: if you’re choosing between these two platforms purely on the medication, it barely matters. Choose on price, user experience, and whether you want to buy seventeen other products from the same company.
The Numbers: What Treatment Costs in 2026
This is where things get practical, and where the decision framework actually lives.
Generic oral finasteride runs $10 to $25 per month at US pharmacies with discount cards. Through DTC telehealth services like Hims or Keeps, it can drop to $5 to $15 monthly. Branded Propecia still costs $70 to $90 a month with zero documented clinical advantage over the generic.
Generic topical minoxidil is $10 to $30 monthly depending on volume. Branded Rogaine roughly doubles that.
Low-dose oral minoxidil, increasingly prescribed off-label after Vañó-Galván et al.’s 2021 multicenter study of 1,404 patients in JAAD documented its efficacy profile, is often under $15 per month in generic form. The cost driver is the prescribing visit ($50 to $150 through telehealth, or potentially covered through in-person dermatology with insurance).
Hair transplantation is a different universe: $4 to $10 per graft for FUE in the US, translating to $10,000 to $35,000 for a typical 2,500 to 3,500 graft case. Turkish clinics run $2,000 to $5,000 for similar graft counts, reflecting labor cost arbitrage more than quality differentials (though quality variance is real).
PRP (platelet-rich plasma) sessions run $500 to $1,500 each, with most protocols calling for three to four sessions the first year. That’s potentially more than an entire year of finasteride plus minoxidil combined.
Insurance generally won’t touch any of this. Pattern hair loss is classified as cosmetic. HSA and FSA accounts may cover prescribed medications and physician visits but typically exclude surgical procedures.
For a more detailed comparison of how Hims and Keeps stack up on staging tools, pricing breakdowns, and clinical documentation, this resource provides a thorough walkthrough with photographic examples.
How a Dermatologist Would Actually Assess You
Neither Hims nor Keeps replaces a real dermatology workup. Here’s what that looks like, per AAD clinical guidelines.
It starts with history: timeline of loss, progressive versus episodic pattern, medications, recent illness, diet changes, family tree. Then pattern distribution to narrow the differential (androgenetic alopecia, telogen effluvium, alopecia areata, scarring alopecias, traction effects).
Trichoscopy (dermoscopy of the scalp) adds detail the naked eye can’t catch. In androgenetic alopecia, you see hair shaft diameter variability of 20% or more, yellow dots from empty follicular ostia, decreased follicular unit density in affected zones with the occipital donor area preserved.
Lab testing is selective. Ferritin, TSH, vitamin D, CBC are reasonable when telogen effluvium is in the differential or diffuse thinning is the presentation. The AAD does not recommend routine androgen panels in men with classic pattern loss because the diagnosis is clinical.
Standardized photography (front, top, sides, back, consistent lighting and head position) is the only reliable way to track change over months. Your phone’s selfie camera in bathroom lighting is not this.
What Else the Literature Actually Supports
A few lifestyle factors have real evidence behind them, and a lot of popular claims don’t.
Smoking accelerates pattern hair loss through microvascular damage, oxidative stress, and androgen effects. Cross-sectional studies show higher rates of androgenetic alopecia in smokers versus matched nonsmokers. If you’re spending $20 a month on finasteride while smoking a pack a day, you’re working against yourself.
Iron deficiency (serum ferritin below 30 ng/mL in women, below 50 ng/mL when hair loss is the concern) contributes to shedding via telogen effluvium. Repleting iron in deficient patients reduces shedding. Supplementing iron when you’re already replete does nothing for your hair.
Severe stress can trigger telogen effluvium two to three months after the event. It typically resolves within six to nine months once the stressor passes, but it may unmask underlying pattern loss that was previously subclinical.
Anabolic steroid use accelerates pattern loss in genetically susceptible men through supraphysiologic androgen exposure. Effects may not fully reverse after discontinuation.
Diet matters only at the extremes. Severe caloric restriction, very low protein intake, and rapid weight loss reliably produce telogen effluvium. Modest dietary improvements beyond correcting specific deficiencies don’t produce visible hair benefits. Biotin supplements are the hair loss equivalent of putting premium gas in a Honda Civic: not harmful, not helpful, just expensive urine.
When to Skip the App and See Someone in Person
Several scenarios call for in-person dermatology rather than a telehealth subscription:
Sudden, diffuse shedding within the last six months suggests telogen effluvium, which needs workup for the precipitating cause, not a finasteride prescription.
Patchy, smooth, well-circumscribed bald spots suggest alopecia areata, an autoimmune condition with a completely different treatment path.
Scalp pain, burning, redness, scaling, or visible scarring suggests a scarring alopecia (lichen planopilaris, frontal fibrosing alopecia, CCCA). These require prompt diagnosis. Delay means permanently destroyed follicles. This is the one scenario where urgency is real.
Hair loss in women with menstrual irregularities, acne, or excess body hair warrants endocrine evaluation for PCOS or other androgen excess states.
Rapid progression in a young patient (more than one Norwood stage per year) merits in-person confirmation and early intervention planning.
And if 12 months of documented, consistent medical therapy hasn’t produced results, reassessment is warranted. “Documented and consistent” doing a lot of heavy lifting in that sentence, because adherence with twice-daily topical minoxidil is notoriously poor.
The AAD’s position is clear: any progressive hair loss that concerns the patient is a legitimate reason for dermatology consultation. That’s a low bar, and intentionally so.
FAQs
How accurate are AI hair-loss assessment tools? AI-based tools provide reasonable orientation for self-screening but do not replace dermatologic evaluation. They’re useful as a starting point for understanding likely stage and treatment direction.
Is finasteride safe? Finasteride is FDA-approved for pattern hair loss at 1 mg daily with a safety profile characterized across more than two decades of use. Sexual side effects are reported in a small percentage of users in randomized trials and are generally reversible on discontinuation. Discuss risks and benefits with a prescribing clinician.
Is hair loss covered by insurance? Pattern hair loss treatment is generally classified as cosmetic and not covered. Some HSA and FSA accounts cover prescribed medications and physician visits.
Is oral minoxidil better than topical? Low-dose oral minoxidil produces effects comparable to topical with better adherence in many patients. The choice depends on side-effect tolerance, patient preference, and clinician guidance.
What is shock loss after a hair transplant? Temporary shedding of native or transplanted hairs in the weeks following a transplant, typically resolving over three to six months as follicles re-enter the growth phase.
Are hair transplants permanent? Transplanted follicles from the genetically resistant donor zone generally retain their resistance to miniaturization and persist long-term. Surrounding native hair may continue thinning, which is why most patients continue medical therapy post-transplant.
Do Hims and Keeps prescribe the same medications? Yes. Both platforms offer finasteride 1 mg and minoxidil 5%, the same FDA-approved active ingredients at the same doses. Differences are in pricing, branding, and ancillary products.
References
- Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
- Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
- Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
- American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
- Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
- Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
- Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.
Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.
Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.
By
